Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREAS SCHMID

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1962663377
CMS profile
761022
Location
KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$15.37

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $15.37 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Insmed, Inc. $15.37 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREAS SCHMID

NPI 1962663377 · CMS profile ID 761022

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962663377?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962663377?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962663377?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1962663377?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $15.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insmed, Inc. $15.3711/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089560266 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,930.13 21
PY2020 $7,244.44 9
PY2023 $1,117.56 9
PY2024 $15.37 1
PY2025 $72.62 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,654.12 9
PY2025 Principal investigator $330,468.44 168
PY2024 Principal investigator $383,470.04 191
PY2023 Principal investigator $688,078.36 235
PY2022 Principal investigator $419,549.56 143
PY2021 Principal investigator $95,534.58 57
PY2019 Principal investigator $7,217.27 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

177 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $2.50 12/31/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749178
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 12/31/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749180
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 12/31/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749182
Principal investigator 1 SANOFI US SERVICES INC. $9,320.40 12/22/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Research Inst Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226081145
Principal investigator 1 SANOFI US SERVICES INC. $20,127.53 12/22/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Research Inst Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226081158
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 12/17/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749116
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 12/17/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749170
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 12/17/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749172
Principal investigator 1 Boehringer Ingelheim International GmbH $25.52 12/17/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749174
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 12/17/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749176
Principal investigator 1 Verona Pharma, Inc. $10,853.55 12/17/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232892017
Principal investigator 1 Verona Pharma, Inc. $226.23 12/17/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232892019
Principal investigator 1 Mannkind Corporation $2,003.51 12/10/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898662
Principal investigator 1 Mannkind Corporation $5,067.50 12/10/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898664
Principal investigator 1 Mannkind Corporation $5,164.10 12/09/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898622
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 12/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749110
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 12/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749112
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 12/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749114
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749164
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749166
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749168
Principal investigator 1 Verona Pharma, Inc. $116.34 12/01/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232892021
Principal investigator 1 Genentech, Inc. $9.51 11/19/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Ph1c proof of activity study of GDC-6988 in patients with COPD and NCFB No dispute reported 06/30/2026 1211620426
Principal investigator 1 Verona Pharma, Inc. $118.89 11/12/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232892011
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,497.98 11/11/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220811702
Principal investigator 1 Insmed, Inc. $7,072.87 11/05/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650072
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 11/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749104
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 11/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749106
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 11/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749108
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749158
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749160
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749162
Principal investigator 1 Verona Pharma, Inc. $21,773.86 10/24/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232892013
Principal investigator 1 Verona Pharma, Inc. $71.43 10/24/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232892015
Principal investigator 1 Mannkind Corporation $6.35 10/23/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898594
Principal investigator 1 Insmed, Inc. $1,248.36 10/22/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650074
Principal investigator 1 CSL Behring $1,000.00 10/15/2025 Non-covered Recipient Entity
Kumc Research Institute, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252668181
Principal investigator 1 CSL Behring $1,201.50 10/15/2025 Non-covered Recipient Entity
Kumc Research Institute, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252668183
Principal investigator 1 CSL Behring $1,750.00 10/15/2025 Non-covered Recipient Entity
Kumc Research Institute, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252668185
Principal investigator 1 CSL Behring $2,350.00 10/15/2025 Non-covered Recipient Entity
Kumc Research Institute, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252668187
Principal investigator 1 CSL Behring $2,670.00 10/15/2025 Non-covered Recipient Entity
Kumc Research Institute, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252668189
Principal investigator 1 CSL Behring $15,650.00 10/15/2025 Non-covered Recipient Entity
Kumc Research Institute, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252668191
Recipient GlaxoSmithKline, LLC. $48.00 10/06/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192179278
Recipient GlaxoSmithKline, LLC. $58.95 10/06/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192179287
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 10/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749098
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 10/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749100
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 10/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749102
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749152
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749154
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749156
Principal investigator 1 Verona Pharma, Inc. $27,181.62 10/01/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232892009
Principal investigator 1 Insmed, Inc. $11,146.03 09/17/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650064
Principal investigator 1 Mannkind Corporation $3,569.12 09/16/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898572
Recipient GlaxoSmithKline, LLC. $113.85 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192177174
Recipient GlaxoSmithKline, LLC. $37.40 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192177178
Recipient GlaxoSmithKline, LLC. $20.94 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192179274
Recipient GlaxoSmithKline, LLC. $34.91 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192179282
Recipient GlaxoSmithKline, LLC. $237.63 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192179292
Recipient GlaxoSmithKline, LLC. $103.36 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192179297
Recipient GlaxoSmithKline, LLC. $999.08 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192179303
Principal investigator 1 Verona Pharma, Inc. $10,886.93 09/03/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232891901
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 09/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748998
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 09/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749092
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 09/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749094
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749134
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749136
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749138
Principal investigator 1 Insmed, Inc. $6,888.84 08/28/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650046
Principal investigator 1 Insmed, Inc. $0.44 08/28/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650050
Principal investigator 1 Insmed, Inc. $0.46 08/28/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650056
Principal investigator 1 Insmed, Inc. $0.46 08/28/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650062
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 08/26/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749140
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 08/26/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749142
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 08/26/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749144
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 08/26/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749146
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 08/26/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749148
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 08/26/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749150
Principal investigator 1 Mannkind Corporation $20,236.61 08/20/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898558
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749082
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749088
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749090
Principal investigator 1 Boehringer Ingelheim International GmbH $95.85 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749118
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749120
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749122
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749124
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749126
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749128
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749130
Principal investigator 1 Boehringer Ingelheim International GmbH $799.00 08/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220749132
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 07/28/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749096
Principal investigator 1 Verona Pharma, Inc. $119.46 07/25/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232891903
Principal investigator 1 Insmed, Inc. $1,783.63 07/23/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650066
Principal investigator 1 Mannkind Corporation $6.35 07/17/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898534
Principal investigator 1 Insmed, Inc. $6,888.84 07/15/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650048
Principal investigator 1 Mannkind Corporation $12.61 07/07/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898530
Principal investigator 1 Insmed, Inc. $0.66 07/03/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650052
Principal investigator 1 Insmed, Inc. $0.92 07/03/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650054
Principal investigator 1 Insmed, Inc. $1.38 07/03/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650058
Principal investigator 1 Insmed, Inc. $11,481.40 07/03/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650060
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 07/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749080
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 07/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749084
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 07/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749086
Principal investigator 1 Genentech, Inc. $8,838.50 06/25/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Ph1c proof of activity study of GDC-6988 in patients with COPD and NCFB No dispute reported 06/30/2026 1211620164
Principal investigator 1 Genentech, Inc. $15,650.00 06/20/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Ph1c proof of activity study of GDC-6988 in patients with COPD and NCFB No dispute reported 06/30/2026 1211620180
Principal investigator 1 Mannkind Corporation $12,250.35 06/19/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898518
Principal investigator 1 Mannkind Corporation $12.66 06/19/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898520
Principal investigator 1 Insmed, Inc. $0.92 06/16/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650028
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,921.00 06/06/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220811698
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $67.96 06/05/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220811700
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 06/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748992
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 06/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748994
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 06/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748996
Principal investigator 1 Insmed, Inc. $277.68 05/28/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650004
Principal investigator 1 Insmed, Inc. $710.22 05/28/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650006
Principal investigator 1 Insmed, Inc. $1,383.40 05/28/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650008
Principal investigator 1 Insmed, Inc. $1,200.00 05/28/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650010
Principal investigator 1 Mannkind Corporation $139.83 05/28/2025 Non-covered Recipient Entity
KUMC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898512
Principal investigator 1 Insmed, Inc. $277.68 05/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650012
Principal investigator 1 Verona Pharma, Inc. $6,902.25 05/02/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232891837
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 05/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748986
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 05/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748988
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 05/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748990
Principal investigator 1 Insmed, Inc. $0.88 04/10/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650020
Principal investigator 1 Insmed, Inc. $16,073.96 04/10/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650022
Principal investigator 1 Insmed, Inc. $1.38 04/10/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650024
Principal investigator 1 Insmed, Inc. $0.92 04/10/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650026
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,868.00 04/04/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220811692
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 04/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748978
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 04/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748980
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 04/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748984
Principal investigator 1 Verona Pharma, Inc. $18,150.00 04/01/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Verona No dispute reported 06/30/2026 1232891841
Principal investigator 1 Insmed, Inc. $0.44 03/17/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649948
Principal investigator 1 Insmed, Inc. $0.92 03/17/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649956
Principal investigator 1 Insmed, Inc. $0.46 03/17/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649962
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 03/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748968
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 03/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748970
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 03/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748972
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 02/25/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748974
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 02/25/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748976
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 02/25/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749078
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $691.00 02/25/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220811696
Principal investigator 1 Insmed, Inc. $154.86 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649964
Principal investigator 1 Insmed, Inc. $534.00 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649966
Principal investigator 1 Insmed, Inc. $277.68 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649968
Principal investigator 1 Insmed, Inc. $133.50 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649970
Principal investigator 1 Insmed, Inc. $53.40 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649972
Principal investigator 1 Insmed, Inc. $600.00 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649974
Principal investigator 1 Insmed, Inc. $53.40 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649976
Principal investigator 1 Insmed, Inc. $600.00 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649978
Principal investigator 1 Insmed, Inc. $534.00 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649980
Principal investigator 1 Insmed, Inc. $154.86 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649982
Principal investigator 1 Insmed, Inc. $277.68 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649984
Principal investigator 1 Insmed, Inc. $534.00 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649986
Principal investigator 1 Insmed, Inc. $444.56 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649988
Principal investigator 1 Insmed, Inc. $534.00 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649990
Principal investigator 1 Insmed, Inc. $534.00 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649992
Principal investigator 1 Insmed, Inc. $1,563.75 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649994
Principal investigator 1 Insmed, Inc. $1,425.58 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649996
Principal investigator 1 Insmed, Inc. $358.05 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649998
Principal investigator 1 Insmed, Inc. $358.05 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650000
Principal investigator 1 Insmed, Inc. $358.05 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650002
Principal investigator 1 Insmed, Inc. $0.44 02/07/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649950
Principal investigator 1 Insmed, Inc. $0.46 02/07/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649952
Principal investigator 1 Insmed, Inc. $0.46 02/07/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649958
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 02/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748962
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 02/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748964
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 02/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748966
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.82 01/27/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220811694
Principal investigator 1 Insmed, Inc. $0.66 01/16/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649944
Principal investigator 1 Insmed, Inc. $0.46 01/16/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649954
Principal investigator 1 Insmed, Inc. $0.46 01/16/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649960
Principal investigator 1 AstraZeneca UK Limited $394.03 01/13/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM
A Randomized, Double-Blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants No dispute reported 06/30/2026 1185547509
Principal investigator 1 Insmed, Inc. $0.44 01/13/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189649946
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,418.24 01/06/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220811690
Principal investigator 1 Boehringer Ingelheim International GmbH $14.37 01/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220748982
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 01/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749074
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 01/01/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220749076